Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue

Stergios Zacharoulis, Adam S. Levy, Susan N. Chi, Sharon Gardner, Marc Rosenblum, Douglas C. Miller, Ira Dunkel, Blanca Diez, Richard Sposto, Lingyun Ji, Shahab Asgharzadeh, Juliette Hukin, Jean Belasco, Ronald Dubowy, Stewart Kellie, Amanda Termuhlen, Jonathan Finlay

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background:. The purpose of this study is to investigate the efficacy of an intensive chemotherapy induction regimen followed by myeloablative chemotherapy and autologous hematopoietic stem cell rescue (AHSCR) in children with newly diagnosed ependymoma. Patients and Methods:. Twenty-nine children less than 10 years of age at diagnosis of ependymoma were enrolled on the "Head Start" studies. Twenty-four patients with localized disease received an induction regimen including five cycles of chemotherapy (cisplatin, vincristine, etoposide cyclophosphamide, and high dose methotrexate for patients with metastatic disease). Following induction, individuals without evidence of disease proceeded to marrow-ablative chemotherapy (thiotepa, carboplatin, and etoposide) with AHSCR. Results:. The estimated 5-year event free survival (EFS) and overall survival (OS) from diagnosis were 12% (±6%) and 38% (±10%), respectively. The toxic mortality amongst this group of 29 patients was 10.3%. Younger age (less than 18 months at diagnosis) was the only statistically significant prognostic factor. The estimated 5-year OS rate for the five patients with metastatic disease at presentation was 80% (±18%). Overall, radiation-free survival at 5 years from diagnosis was 8% (±5%). Conclusions:. The use of an intensive induction chemotherapy regimen including myeloablative chemotherapy followed by AHSCR in newly diagnosed young children with ependymoma is not superior to other previously reported chemotherapeutic strategies.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalPediatric Blood and Cancer
Volume49
Issue number1
DOIs
StatePublished - Jul 2007

Fingerprint

Ependymoma
Induction Chemotherapy
Stem Cells
Drug Therapy
Hematopoietic Stem Cells
Etoposide
Thiotepa
Survival
Poisons
Carboplatin
Vincristine
Methotrexate
Cyclophosphamide
Cisplatin
Disease-Free Survival
Survival Rate
Bone Marrow
Radiation
Mortality

Keywords

  • Chemotherapy
  • CNS tumors
  • Ependymoma
  • Transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. / Zacharoulis, Stergios; Levy, Adam S.; Chi, Susan N.; Gardner, Sharon; Rosenblum, Marc; Miller, Douglas C.; Dunkel, Ira; Diez, Blanca; Sposto, Richard; Ji, Lingyun; Asgharzadeh, Shahab; Hukin, Juliette; Belasco, Jean; Dubowy, Ronald; Kellie, Stewart; Termuhlen, Amanda; Finlay, Jonathan.

In: Pediatric Blood and Cancer, Vol. 49, No. 1, 07.2007, p. 34-40.

Research output: Contribution to journalArticle

Zacharoulis, S, Levy, AS, Chi, SN, Gardner, S, Rosenblum, M, Miller, DC, Dunkel, I, Diez, B, Sposto, R, Ji, L, Asgharzadeh, S, Hukin, J, Belasco, J, Dubowy, R, Kellie, S, Termuhlen, A & Finlay, J 2007, 'Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue', Pediatric Blood and Cancer, vol. 49, no. 1, pp. 34-40. https://doi.org/10.1002/pbc.20935
Zacharoulis, Stergios ; Levy, Adam S. ; Chi, Susan N. ; Gardner, Sharon ; Rosenblum, Marc ; Miller, Douglas C. ; Dunkel, Ira ; Diez, Blanca ; Sposto, Richard ; Ji, Lingyun ; Asgharzadeh, Shahab ; Hukin, Juliette ; Belasco, Jean ; Dubowy, Ronald ; Kellie, Stewart ; Termuhlen, Amanda ; Finlay, Jonathan. / Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. In: Pediatric Blood and Cancer. 2007 ; Vol. 49, No. 1. pp. 34-40.
@article{8490cd76b002411eaa54ec86db5178df,
title = "Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue",
abstract = "Background:. The purpose of this study is to investigate the efficacy of an intensive chemotherapy induction regimen followed by myeloablative chemotherapy and autologous hematopoietic stem cell rescue (AHSCR) in children with newly diagnosed ependymoma. Patients and Methods:. Twenty-nine children less than 10 years of age at diagnosis of ependymoma were enrolled on the {"}Head Start{"} studies. Twenty-four patients with localized disease received an induction regimen including five cycles of chemotherapy (cisplatin, vincristine, etoposide cyclophosphamide, and high dose methotrexate for patients with metastatic disease). Following induction, individuals without evidence of disease proceeded to marrow-ablative chemotherapy (thiotepa, carboplatin, and etoposide) with AHSCR. Results:. The estimated 5-year event free survival (EFS) and overall survival (OS) from diagnosis were 12{\%} (±6{\%}) and 38{\%} (±10{\%}), respectively. The toxic mortality amongst this group of 29 patients was 10.3{\%}. Younger age (less than 18 months at diagnosis) was the only statistically significant prognostic factor. The estimated 5-year OS rate for the five patients with metastatic disease at presentation was 80{\%} (±18{\%}). Overall, radiation-free survival at 5 years from diagnosis was 8{\%} (±5{\%}). Conclusions:. The use of an intensive induction chemotherapy regimen including myeloablative chemotherapy followed by AHSCR in newly diagnosed young children with ependymoma is not superior to other previously reported chemotherapeutic strategies.",
keywords = "Chemotherapy, CNS tumors, Ependymoma, Transplantation",
author = "Stergios Zacharoulis and Levy, {Adam S.} and Chi, {Susan N.} and Sharon Gardner and Marc Rosenblum and Miller, {Douglas C.} and Ira Dunkel and Blanca Diez and Richard Sposto and Lingyun Ji and Shahab Asgharzadeh and Juliette Hukin and Jean Belasco and Ronald Dubowy and Stewart Kellie and Amanda Termuhlen and Jonathan Finlay",
year = "2007",
month = "7",
doi = "10.1002/pbc.20935",
language = "English (US)",
volume = "49",
pages = "34--40",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue

AU - Zacharoulis, Stergios

AU - Levy, Adam S.

AU - Chi, Susan N.

AU - Gardner, Sharon

AU - Rosenblum, Marc

AU - Miller, Douglas C.

AU - Dunkel, Ira

AU - Diez, Blanca

AU - Sposto, Richard

AU - Ji, Lingyun

AU - Asgharzadeh, Shahab

AU - Hukin, Juliette

AU - Belasco, Jean

AU - Dubowy, Ronald

AU - Kellie, Stewart

AU - Termuhlen, Amanda

AU - Finlay, Jonathan

PY - 2007/7

Y1 - 2007/7

N2 - Background:. The purpose of this study is to investigate the efficacy of an intensive chemotherapy induction regimen followed by myeloablative chemotherapy and autologous hematopoietic stem cell rescue (AHSCR) in children with newly diagnosed ependymoma. Patients and Methods:. Twenty-nine children less than 10 years of age at diagnosis of ependymoma were enrolled on the "Head Start" studies. Twenty-four patients with localized disease received an induction regimen including five cycles of chemotherapy (cisplatin, vincristine, etoposide cyclophosphamide, and high dose methotrexate for patients with metastatic disease). Following induction, individuals without evidence of disease proceeded to marrow-ablative chemotherapy (thiotepa, carboplatin, and etoposide) with AHSCR. Results:. The estimated 5-year event free survival (EFS) and overall survival (OS) from diagnosis were 12% (±6%) and 38% (±10%), respectively. The toxic mortality amongst this group of 29 patients was 10.3%. Younger age (less than 18 months at diagnosis) was the only statistically significant prognostic factor. The estimated 5-year OS rate for the five patients with metastatic disease at presentation was 80% (±18%). Overall, radiation-free survival at 5 years from diagnosis was 8% (±5%). Conclusions:. The use of an intensive induction chemotherapy regimen including myeloablative chemotherapy followed by AHSCR in newly diagnosed young children with ependymoma is not superior to other previously reported chemotherapeutic strategies.

AB - Background:. The purpose of this study is to investigate the efficacy of an intensive chemotherapy induction regimen followed by myeloablative chemotherapy and autologous hematopoietic stem cell rescue (AHSCR) in children with newly diagnosed ependymoma. Patients and Methods:. Twenty-nine children less than 10 years of age at diagnosis of ependymoma were enrolled on the "Head Start" studies. Twenty-four patients with localized disease received an induction regimen including five cycles of chemotherapy (cisplatin, vincristine, etoposide cyclophosphamide, and high dose methotrexate for patients with metastatic disease). Following induction, individuals without evidence of disease proceeded to marrow-ablative chemotherapy (thiotepa, carboplatin, and etoposide) with AHSCR. Results:. The estimated 5-year event free survival (EFS) and overall survival (OS) from diagnosis were 12% (±6%) and 38% (±10%), respectively. The toxic mortality amongst this group of 29 patients was 10.3%. Younger age (less than 18 months at diagnosis) was the only statistically significant prognostic factor. The estimated 5-year OS rate for the five patients with metastatic disease at presentation was 80% (±18%). Overall, radiation-free survival at 5 years from diagnosis was 8% (±5%). Conclusions:. The use of an intensive induction chemotherapy regimen including myeloablative chemotherapy followed by AHSCR in newly diagnosed young children with ependymoma is not superior to other previously reported chemotherapeutic strategies.

KW - Chemotherapy

KW - CNS tumors

KW - Ependymoma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=34249799620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249799620&partnerID=8YFLogxK

U2 - 10.1002/pbc.20935

DO - 10.1002/pbc.20935

M3 - Article

C2 - 16874765

AN - SCOPUS:34249799620

VL - 49

SP - 34

EP - 40

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -